{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:14:54Z","timestamp":1794129294849,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejca.2017.09.019","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T22:45:14Z","timestamp":1508453114000},"page":"248-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis"],"prefix":"10.1016","volume":"86","author":[{"given":"Cindy","family":"Franklin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Rooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Milsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Herz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt Werner","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dittmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2017.09.019_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2017.09.019_bib2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2017.09.019_bib3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2017.09.019_bib4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2017.09.019_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.09.019_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2017.09.019_bib7","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.09.019_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2017.09.019_bib9","first-page":"11","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma","volume":"10","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"issue":"15","key":"10.1016\/j.ejca.2017.09.019_bib10","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2017.09.019_bib11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","article-title":"Ipilimumab-induced perforating colitis","volume":"47","author":"Mitchell","year":"2013","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.ejca.2017.09.019_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3109\/0284186X.2012.682630","article-title":"Severe colitis while responding to ipilimumab in metastatic melanoma","volume":"51","author":"Slingerland","year":"2012","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2017.09.019_bib13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.09.019_bib14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.09.019_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijid.2017.01.028","article-title":"Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm","volume":"56","author":"Rao","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.ejca.2017.09.019_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063818","article-title":"A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejca.2017.09.019_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1128611","article-title":"Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis","volume":"5","author":"Lankes","year":"2016","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.ejca.2017.09.019_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0000000000000081","article-title":"Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab","volume":"38","author":"Uslu","year":"2015","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.ejca.2017.09.019_bib19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.dld.2005.01.011","article-title":"Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection","volume":"37","author":"Maconi","year":"2005","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.ejca.2017.09.019_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3748\/wjg.v13.i5.754","article-title":"Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan","volume":"13","author":"Minami","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.ejca.2017.09.019_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00384-017-2752-5","article-title":"Cytomegalovirus, inflammatory bowel disease, and anti-TNFalpha","volume":"32","author":"Campos","year":"2017","journal-title":"Int J Colorectal Dis"},{"issue":"Pt 11","key":"10.1016\/j.ejca.2017.09.019_bib22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1099\/jmm.0.45629-0","article-title":"Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome","volume":"53","author":"Kishore","year":"2004","journal-title":"J Med Microbiol"},{"issue":"9","key":"10.1016\/j.ejca.2017.09.019_bib23","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/ibd.21275","article-title":"Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?","volume":"16","author":"Lawlor","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.ejca.2017.09.019_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.ejca.2017.09.019_bib25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3748\/wjg.v22.i3.1321","article-title":"Cytomegalovirus in inflammatory bowel disease: a systematic review","volume":"22","author":"Romkens","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.ejca.2017.09.019_bib26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/00007890-199504000-00010","article-title":"Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation","volume":"59","author":"Schmidt","year":"1995","journal-title":"Transplantation"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2017.09.019_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1016\/j.ejca.2017.09.019_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.ejca.2017.09.019_bib29","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1097\/MIB.0000000000000556","article-title":"Detection of cytomegalovirus in patients with inflammatory bowel disease: where to biopsy and How many biopsies?","volume":"21","author":"McCurdy","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.ejca.2017.09.019_bib30","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ibd.20498","article-title":"Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy","volume":"14","author":"Domenech","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.ejca.2017.09.019_bib31","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/ibd.20253","article-title":"Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies","volume":"13","author":"Yoshino","year":"2007","journal-title":"Inflamm Bowel Dis"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491731300X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491731300X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T18:57:58Z","timestamp":1535309878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491731300X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":31,"alternative-id":["S095980491731300X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.09.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}